Subsequent Events (Notes) |
3 Months Ended |
---|---|
Dec. 31, 2019 | |
Subsequent Event [Line Items] | |
Subsequent Events [Text Block] | NOTE 17—SUBSEQUENT EVENTS Contingent Consideration In November 2019, the Company received new regulatory information and now expects to achieve an additional $10.0 million contingent regulatory milestone related to the MyoScience Acquisition, which can be made in either cash or shares of the Company’s common stock, or a combination thereof, at the election of MyoScience shareholders. As a result, in the fourth quarter of 2019, the Company expects to record a charge to acquisition-related charges of approximately $9.0 million. For more information regarding contingent milestone payments related to the MyoScience Acquisition, refer to Note 4, MyoScience Acquisition.
|